NJ Judge Invalidates Patent For Janssen Cancer Drug Zytiga
Law360 (October 29, 2018, 8:52 PM EDT) -- A New Jersey federal judge has invalidated a patent covering Janssen Biotech Inc.’s blockbuster oncology medication Zytiga, but said a host of generic-drug makers would have infringed that patent with their oncoming drugs had it been valid.
Following a July bench trial, U.S. District Judge Kevin McNulty on Friday issued a 70-page opinion handing victory to several generic-drug companies. He found that combining the two drugs that make up U.S. Patent No. 8,822,438 was “less like serendipity and more like inevitability.”
The judge is considering a stay during appeal, and has required the status quo to stay through Tuesday and barred...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!